RT Journal Article
SR Electronic
T1 Effectiveness of Covishield vaccine in preventing Covid-19 – A test-negative case-control study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.19.21260693
DO 10.1101/2021.07.19.21260693
A1 Stuti Pramod
A1 Dhanajayan Govindan
A1 Premkumar Ramasubramani
A1 Sitanshu Sekhar Kar
A1 Rakesh Aggarwal
A1 JIPMER vaccine effectiveness study group
A1 Nandhini Manoharan
A1 Palanivel Chinnakali
A1 Mahalakshmy Thulasingam
A1 Sonali Sarkar
A1 Molly Mary Thabah
YR 2021
UL http://medrxiv.org/content/early/2021/07/22/2021.07.19.21260693.abstract
AB Introduction This study was aimed at assessing the vaccine effectiveness (VE) of Covishield, which is identical to the AstraZeneca vaccine, in preventing laboratory-confirmed Covid-19.Methods Using a test-negative case-control design, information on vaccination status of cases with Covid-19 among healthcare workers in our institution in Puducherry, India, and an equal number of matched controls, i.e., positive and negative for SARS-CoV-2 by RT-PCR, was obtained. The cases and controls were matched for age (±3 years) and date of testing (±3 days). The groups were compared using multivariable conditional logistic regression to calculate odds ratios (OR), with adjustment for gender, occupational role, presence of symptoms and presence of a comorbidity condition. Per cent vaccine effectiveness (VE) was calculated as 100 x (1-adjusted odds ratio).Results Using data from 360 case-control pairs, VE of one dose and of two doses, in providing protection against Covid-19 was 49% (95% CI: 17%-68%) and 54% (27%-71%), respectively. In view of a difference in the proportion of cases and controls who had symptoms, a separate analysis of data from 203 pairs where both the case and the control had symptoms was done, which showed VE of 58% (28%-75%) and 64% (38%-78%) after one dose and two doses, respectively. Among cases with moderately severe disease that required oxygen therapy, VE following any number of vaccine doses was 95% (44%-100%).Conclusion Covishield vaccine protected significantly against Covid-19, with the protection after two doses being slightly higher than after one dose, and a particularly high protection rate against severe forms of disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was permitted by the Institute’s (Jawaharlal Institute of Postgraduate Medical Education and Research) Ethics Committee (Project No. JIP/IEC/2021/233).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAs per the institute’s ethics guidelines, the ethics committee reserves the rights on the datasets which protects the privacy of research data for up to three years after completion of the studies. Therefore, the dataset cannot be shared at this point in time. In case of any further queries or clarifications regarding the institute’s ethics guidelines on sharing of research data, the committee may be contacted through their official email: iechumanstudiesjipmer{at}gmail.com The data may be accessed from the JIPMER Ethics Committee (contact: iechumanstudiesjipmer{at}gmail.com) after three years of completion of the project, for those who meet institute’s criteria for access to confidential data.